Peninsula biotech stock loses 80% after eye drug's late-stage study fails
February 23, 2022 at 18:00 PM EST
The company still has a quartet of late-stage trials with the drug in various eye diseases and more than $700 million in cash.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|